UNSPSC 51413005: Mannitol hexanitrate

This classification denotes a vasodilating agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 99AU28W1G9. European Medicines Agency schedules Mannitol hexanitrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08642MIG. Mannitol hexanitrate generally arises in the molecular formula C6H8N6O18.

UNSPSC 51413005 Mannitol hexanitrate is a Commodity code that encompasses advanced life support medications and other pharmaceuticals procured by state and local government health and emergency services agencies. State and local governments buy specific branded and generic medications—including vasopressors, antiarrhythmics, and other critical-care agents—through sealed competitive bidding and cooperative purchasing frameworks. Issuing bodies include municipal fire and rescue departments, state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across state agencies, counties, and local government facilities. Procurement typically requires vendors to meet FDA compliance, Good Manufacturing Practice certification, Drug Supply Chain Security Act compliance, comprehensive insurance, and safety documentation including OSHA-compliant Safety Data Sheets and accessibility conformance reporting.

Recent activity shows solicitations across Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued an IFB (26P00188) in April 2026 for Advanced Life Support Medications to supply Tampa Fire Rescue with four specific medication line items—Labetalol, Epinephrine, Adenosine, and Diltiazem—with a response deadline of April 8, 2026 and an estimated contract value of $40,000, including a 5 percent bid discount for Small Local Business Enterprise participation. The Texas Health and Human Services Commission posted an RFI (HHS0017013) in April 2026 exploring direct-to-manufacturer prescription fulfillment capabilities outside traditional pharmacy benefit manager and group purchasing organization channels, signaling potential future formal procurement as the state develops strategy. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products, closing March 26, 2026, requiring distribution through three authorized wholesalers and supporting multiple state and local government facilities across Minnesota and Oregon, with contract effectiveness July 1, 2026.